遗传性血管的预防:一个英国的德尔菲共识
Patrick F K Yong1, Rachel Annals2, Lavanya Diwakar3
1Department of Immunology, Frimley Health NHS Foundation Trust, Frimley, UK.
Clinical and experimental immunology
|March 8, 2024
概括
遗传性血管 (HAE) 的管理需要更新. 目前英国对长期预防 (LTP) 的准入过于简单,可能会排除可能从治疗中受益的患者.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 遗传性血管 (HAE) 是一种罕见的,危及生命的遗传性疾病,其特点是经常出现发作.
- 目前的治疗策略包括按需药物治疗和预防,长期预防 (LTP) 是国际上推用于疾病控制的.
- 英国对HAE管理的最后一个共识是在2014年,早于新的预防药物.
研究的目的:
- 更新英国关于遗传性血管 (HAE) 管理的临床共识,重点关注长期预防 (LTP).
- 评估英国现代LTP代理商的当前访问标准.
- 确定改善HAE患者护理的领域,包括专家中心,远程监测和心理支持.
主要方法:
- 采用了Delphi过程,从英国的临床医生和患者中收集共识.
- 关于LTP和更广泛的HAE管理的陈述经过多轮开发和改进.
主要成果:
- 达成共识的是,仅基于发作频率的现代LTP的英国准入标准过于简单,可能使符合条件的患者处于不利地位.
- 对于HAE护理专家中心的重要性达成一致.
- 远程监测和患者报告的结果测量 (PROM) 被认为是提高患者护理的有价值工具.
结论:
- 目前英国对HAE长期预防的准入标准需要修订,而不仅仅是简单的攻击频率.
- 专家中心,远程监控和PROM对于优化HAE管理至关重要.
- 心理健康支持是HAE患者的一个重要未满足的需求,需要未来的研究.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
294
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
294
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
512
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696


